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Pulmonary alveolar microlithiasis is a rare diffuse lung disease characterized by widespread sand-like
intra-alveolar calciﬁcations (calcospherites composed of calcium and phosphorus). Around 800 cases
have been reported in the literature to date. We report here a case of a 35 years old female with pro-
longed h/o of exertional dyspnoea and mild cough. Clinical examination was mostly normal. Her Chest X-
Ray revealed bilateral multiple nodular opacities (sand storm appearance). CT Scan chest showed diffuse
micronodular calciﬁcations with septal thickening, compatible with alveolar microlithiasis. Pulmonary
function tests showed moderately restrictive lung disease. Bronchoscopic alveolar lavage revealed cal-
cospherites in the alveloli and bronchi conﬁrming the diagnosis of pulmonary alveolar microlithiasis.
© 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
A 25 years old married female, mother of two children came in
the outpatient clinic with complaints of persistent cough for the
last 10 years and breathlessness for six years with off and on fever
during this period. According to the patient she was well 10 years
ago when she started getting bouts of dry cough especially at
night so much so that she used to wake up from sleep. Also she
started having episodes of fever along with cough which some-
times resolved spontaneously (after variable periods of time) and
at other times she took treatment from a doctor for which she had
to travel far as she resided in a far ﬂung area of Baluchistan desert
in Pakistan with almost no medical facilities. After few years of
intractable cough, she as well started noticing breathlessness
which was initially on exertion and later on at rest also with ex-
acerbations at the time of fever. She never had hemoptysis but had
history of passing gritty particles in sputum. There was no history
of orthopnea, paroxysmal nocturnal dyspnoea, body swelling,
urinary or gastrointestinal complaint and she was never hospi-
talized. For ten years, she consulted many general practitioners
and consultants and considering her chest Xrays has tuberculosis
like radiological appearance, she was prescribed anituberculous
therapy thrice, each upto 8e9 months duration. In addition, she
has had multiple courses of antibiotics and both oral and inhaled).
n open access article under the Ccorticosteroids. There was no improvement from any of these
drugs.
She presented to us with severe exertional dyspnoea for the last
2 weeks. On examination, she was afebrile, tachypnoeac with res-
piratory rate of 32 breaths per minute with normal blood pressure
and pulse. Her Chest examination revealed scattered crepitations
all over the chest but otherwise no other abnormality. Rest of her
systemic examination was normal. Her blood oxygen saturation
while breathing room air was 82% while arterial blood gas analysis
showed low pressures of Oxygen.
Her laboratory tests showed hemoglobin level of 11.5 gm/dl, TLC
of 9500/cmm with 60% neutrophils and 25% lymphocytes and
elevated ESR of 30 mm in 1st hour. Liver function tests, serum
electrolytes, renal function tests, serum parathyroid hormone and
vitamin D were all within normal range. Pulmonary function tests
showedmoderately restrictive lung diseasewhichwas not reversed
with bronchodilators Sputum smear for AFB was negative three
times and culture showed no growth. Her Chest Xray (Fig. 1A, B and
C) showed bilateral diffuse ﬁne nodules predominantly in the
middle and lower Zones (Sand Storm Appearance). Her CT Scan
Chest images (Fig. 2A, B and C) demonstrated widespread tiny
micro calciﬁcations throughout the lungs with septal thickening
and ground-glass opaciﬁcation. Later on, Bronchoscopic alveolar
lavage was performed which revealed rehtypical microliths and
cytologic smears showed extracellular and intracellular concentri-
cally round microliths conﬁrming the diagnosis of pulmonary
alveolar microlithiasis. She was symptomatically treated by Intra-
venous Moxiﬂoxacin to cover possible infections and oxygenC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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advice of long term oxygen therapy at home. Because of her travel
logistic difﬁculties, she is on 4monthly (May 2015, September 2015,
January 2016 and May 2016) follow up and regular till now.2. Discussion
Pulmonary alveolar microlithiasis (PAM) is a rare diffuse lung
disease characterized by widespread sand-like intra-alveolar cal-
ciﬁcations (calcospherites composed of microliths composed of
calcium and phosphorus). First described in 1856 by Friederich [1],
and then by Harbitz [2] (hence some times also known as HarbitzFig. 1. A. Chest x ray showing bilateral diffuse ﬁne nodules predominantly in the
middle and lower Zones (Sand Storm Appearance). B. Close view of left upper zone. C
Close view of right upper zone.Syndrome); It was named Pulmonary alveolar microlithiasis by
PUHR in 1933 [3]. Around 800 cases have been reported till date in
medical literature with two third in Europe and Asia, particularly
Italy, Turkey and Japan [4,5].
PAM is an autosomal recessive disease with Sporadic and fa-
milial cases accounting for 30e50% [6,7] of the cases with no spe-
ciﬁc sex predilection but male predominance has been described in
sporadic cases [8]. PAM is thought to be caused by mutations of the
SLC34A2 gene. It encodes a type IIb sodium-dependent phosphate
co-transporter (NaPi-IIb). SLC34A2 is primarily expressed in the
lung and only in type II pneumocytes [9,10]. These cells are
responsible for production of surfactant. Loss of function of theFig. 2. A & B. Axial view of CT Scan Chest showing widespread tiny micro calciﬁcations
throughout the lungs with septal thickening and ground-glass opaciﬁcation. C. Coronal
View of CT Scan Chest showing micro calciﬁcations.
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which in turn may lead to formation of intra alveolar microliths
(calcospherites) as a result of phosphate-chelating calcium in the
extracellular ﬂuid [11].
PAM is a diseasewith clinical and radiological dissociation and is
mostly diagnosed incidentally during pulmonary radiography of
the chest for other reasons while many patients have no clinical
symptoms [12,13]. The disease is usually discovered from birth up
to 40 yrs of age. In symptomatic patients, typical complaints are
dyspnoea, cough, chest pain and asthenia [16]. Cough may occur at
any stage of disease even with expectoration of microliths. The
disease is usually indolent with slow progression and leads to
pulmonary ﬁbrosis, respiratory failure and cor pulmonale [14].
The characteristic picture of PAM on the chest radiograph shows
inﬁltrates as ﬁne sand-like calciﬁc micronodules also called 'sand-
storm lung', diffusely involving both lungs and usually more
marked in middle and lower zones [15].
Differential diagnosis include miliary tuberculosis, sarcoidosis,
pneumoconiosis, pulmonary hemosiderosis, amyloidosis, and
metastatic pulmonary calciﬁcations associated with chronic renal
failure.
The characteristic CT chest ﬁndings are calciﬁed thickening of
interlobular septa, bronchovascular bundles, and pleura [16]. CT
shows symmetrical abnormalities in the lungs, usually as marked
calciﬁcations. The calciﬁcations are most prominent in peripheral,
mediastinal and ﬁssural subpleural regions and each lobe is sur-
rounded by a ﬁne dense outline, giving the overall appearance of a
stony lung with areas of ground-glass opacity commonly visible.
Subpleural multiple small cysts are also present.
Extrapulmonary calciﬁcations can occur with PAM, like medul-
lary nephrocalcinosis nephrolithiasis, calciﬁcation of the lumbar
sympathetic chain, possible testicular involvement, punctate cal-
ciﬁcations in the seminal vesicles, epididymal and periurethral
calciﬁcations causing obstructive azospermia [17,18].
Routine blood biochemistry including serum calcium concen-
tration, hepatic, renal and parathyroid functions are usually normal.
The deterioration of the pulmonary function may be useful to
monitor disease activity and disease progression. Most of the cases
either have normal pulmonary function or amild restrictive pattern
The identiﬁcation of the SLC34A2 gene mutation (where available)
also suggests the diagnosis. Serum concentrations of the surfactant
proteins A and D(SP-A and SP-D) are elevated in the patients with
PAM, and can be the markers to monitor the activity and progres-
sion of the disease [19].
The Radiology is usually pathognomonic for diagnosis but
sometimes ﬁbreoptic broncoscopy with BAL or lung biopsy
showing microliths is required to conﬁrm the diagnosis. The mi-
croliths are rounded, oval and lobular concentric laminated in
appearance. The composition of the calciﬁcations is calcium and
phosphate, in a ratio of 2:1.
There is no known effective treatment for PAM, with theexception of lung transplantation [20]. Home-based oxygen ther-
apy is often necessary as the disease progresses. Symptomatic and
some radiological improvement with use of steroids, disodium et-
idronate and therapeutic BAL has been observed in very few cases
till date [21]. Long-term survival time is still uncertain but is usually
more than 20 years.
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